# US 2012/0252823 A1 · Adenosine receptor agonists, partial agonists, and antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252823 A1
- Document ID: US20120252823A1
- Status: Published application
- Kind: A1
- Application number: 13/479,973
- Filed: 2012-05-24
- Published: 2012-10-04
- Earliest claimed: 2008-08-01
- Assignees: Services; The United States of America, as represented by the Secretary, Department of Health and Human
- Inventors: Kenneth A. Jacobson; Dilip K. Tosh
- Web page: https://patentgrep.com/patent/US20120252823A1

## CPC

- C07D 473/34: attached in position 6, e.g. adenine
- A61K 31/52: Purines, e.g. adenine
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are A3 adenosine receptor antagonists and/or partial agonists and A1 adenosine receptor agonists and/or partial agonists of formula (I): wherein R1 to R5 are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The A3 AR antagonists or partial agonists find use in treating a number of diseases such as cancer, glaucoma, and inflammatory diseases, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs. The A1 AR agonists and partial agonists find use in treating diseases such as seizures, convulsion, stroke, diabetes, pain, arrhythmias, depression, and anxiety and in cardioprotection or neuroprotection.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A compound of formula (I)
wherein
R1 is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 dicycloalkyl C1-C6 alkyl, C7-C12 bicycloalkyl C1-C6 alkyl, C7-C14 tricycloalkyl C1-C6 alkyl, —CH(Ra)(Rb), C6-C14 aryl, C6-C14 aryl C1-C6 alkyl, C6-C14 diaryl C1-C6 alkyl, and C6-C14 aryl C1-C6 alkoxy, wherein Ra and Rb are independently selected from the group consisting of C1-C6 alkyl, C3-C8 cycloalkyl, and C6-C14 aryl,
wherein the aryl portion of R1 is optionally substituted with one or more substituents selected from the group consisting of halo, amino, hydroxyl, carboxy, C1-C6 alkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, C1-C6 dialkyl aminocarbonyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C6-C14 aryloxy, hydroxy C1-C6 alkyl, hydroxy C2-C6 alkenyl, hydroxy C2-C6 alkynyl, carboxy C1-C6 alkyl, carboxy C2-C6 alkenyl, carboxy C2-C6 alkynyl, aminocarbonyl C1-C6 alkyl, aminocarbonyl C2-C6 alkenyl, aminocarbonyl C2-C6 alkynyl, and C≡C—(CH2)n—COR7 wherein R7 is selected from the group consisting of OH, OR8, and NR9R10, wherein R8 is selected from the group consisting of C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 dicycloalkyl C1-C6 alkyl, C7-C12 bicycloalkyl C1-C6 alkyl, C7-C14 tricycloalkyl C1-C6 alkyl, C6-C14 aryl, C6-C14 aryl C1-C6 alkyl, C6-C14 and diaryl C1-C6 alkyl; and R9 and R10 are independently selected from the group consisting of hydrogen, C1-C6 alkyl, and (CH2)nR11 wherein R11 is NR12R13, wherein R12 and R13 are independently selected from the group consisting of hydrogen, C1-C6 alkyl, and COR14 wherein R14 is hydrogen or C1-C6 alkyl; wherein n is an integer from 1 to 10; and the alkyl or cycloalkyl portion of R1 is optionally substituted with one or more substituents selected from the group consisting of halo, amino, C1-C6 alkyl, C1-C6 alkoxy, C6-C14 aryloxy, C1-C6 hydroxyalkyl, C2-C6 hydroxyalkenyl, C2-C6 hydroxy alkynyl, aminocarbonyl C1-C6 alkoxy, and C6-C14 aryl C1-C6 alkoxy;
R2 is selected from the group consisting of hydrogen, halo, amino, hydrazido, mercapto, C1-C20 alkylamino, C6-C14 aryl amino, C6-C14 aryloxy, C1-C20 alkyl, C1-C20 alkoxy, C1-C20 thioalkoxy, pyridylthio, heterocyclyl, C7-C12 cycloalkyl C1-C20 alkyl, C7-C12 bicycloalkyl C1-C20 alkyl, C7-C12 bicycloalkenyl C1-C20 alkyl, C6-C14 aryl C1-C20 alkyl, C2-C20 alkenyl, C7-C12 cycloalkyl C2-C20 alkenyl, C7-C12 bicycloalkyl C2-C20 alkenyl, C7-C12 bicycloalkenyl C2-C20 alkenyl, C6-C14 aryl C2-C20 alkenyl, C2-C20 alkynyl, carboxy alkyl C2-C20 alkynyl, —C≡C—(CH2)m—C(═O)—O—C1-C6 alkyl, —C≡C—(CH2)m—C(═O)—NH—(CH2)n—NH2, —C≡C—(CH2)m—C1-C6 alkyl, —C≡C—(CH2)m-aryl, wherein m and n are independently 1 to 10, C7-C12 cycloalkyl C2-C20 alkynyl, C7-C12 bicycloalkyl C2-C20 alkynyl, C7-C12 bicycloalkenyl C2-C20 alkynyl, C6-C14 aryl C2-C20 alkynyl, and the alkyl, cycloalkyl, heterocyclyl, or aryl portion of R2 is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, amino, alkylamino, dialkylamino, sulfur, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkyl aminocarbonyl, aminoalkyl aminocarbonyl, pyridyl, alkyl pyridyl, haloalkyl pyridyl, trihaloalkyl pyridyl, carboxy pyridyl, pyrazinyl, quinolinyl, quinazolinyl, and trialkylsilyl, or wherein the heterocyclyl is optionally substituted with an optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, carboxyl, sulfonyl, —C(O)ORe, —CH(OH)Re, or C(O)NReRf, wherein Re or Rf is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aralkyl, optionally substituted aryl, or optionally substituted heteroaryl;
R3 and R4 are independently selected from the group consisting of hydroxyl, amino, thiol, ureido, C1-C6 alkyl carbonylamino, hydroxy C1-C6 alkyl, and hydrazinyl; and
R5 is selected from the group consisting of hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, heteroaryl, and C1-C6 aminoalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 29)

The compound or salt of claim 29, wherein R1 is selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C6 alkyl, C3-C8 dicycloalkyl C1-C6 alkyl, C7-C14 tricycloalkyl C1-C6 alkyl, —CH(Ra)(Rb), and C6-C14 aryl C1-C6 alkyl, wherein Ra and Rb are independently selected from the group consisting of C1-C6 alkyl, C3-C8 cycloalkyl, and C6-C14 aryl,
wherein the aryl portion of R1 is optionally substituted with one or more substituents selected from the group consisting of halo, C1-C6 alkoxy, and halo C1-C6 alkoxy.

### Claim 31 (depends on 29)

The compound or salt of claim 29, wherein R2 is halo.

### Claim 32 (depends on 29)

The compound or salt of claim 29, wherein R3 and R4 are hydroxyl.

### Claim 33 (depends on 29)

The compound or salt of claim 29, wherein R5 is hydrogen.

### Claim 34 (depends on 29)

The compound or salt of claim 29, wherein R2 is chloro.

### Claim 35 (depends on 29)

The compound or salt of claim 29, wherein R1 is:
R2 is chloro, R3 and R4 are hydroxyl, and R5 is hydrogen.

### Claim 36 (depends on 29)

The compound or salt of claim 29, wherein the compound is of the formula (Ia):
wherein:

### Claim 37 (depends on 29)

A pharmaceutical composition comprising a compound or salt of claim 29 and a pharmaceutically acceptable carrier.

### Claim 38 (depends on 29)

A method of treating a disease in a mammal comprising administering to the mammal an effective amount of a compound of claim 29 or a pharmaceutically acceptable salt thereof, wherein the disease is selected from the group consisting of seizures, convulsion, stroke, diabetes, pain, arrhythmias, depression, and anxiety.

### Claim 39 (depends on 29)

A method of cardioprotecting or neuroprotecting a mammal in need thereof comprising administering to the mammal an effective amount of a compound of claim 29 or a pharmaceutically acceptable salt thereof, wherein in the cardioprotection is in ischemia and the neuroprotection is in ischemia, seizure, or epilepsy.

### Claim 40 (depends on 29)

A method for partially or fully activating an A1 adenosine receptor in a mammal in need thereof comprising administering to the mammal an effective amount of a compound of claim 29 or a pharmaceutically acceptable salt thereof.
